Hinge Health (HNGE) drew fresh attention after its recent share performance, with the stock closing at $104.96. Investors are weighing that price against its current business scale and reported profitability.
Recent trading has come with short term noise, including a small 1 day share price return decline. However, the 7 day share price return of 7.1% and 30 day share price return of 13.6% point to building momentum for Hinge Health. Over a longer stretch, a year to date share price return of 130.4% and 1 year total shareholder return of 106.9% signal a stock that has already moved a long way. This raises sharper questions about how today’s US$104.96 level lines up with the business scale and risk profile investors are now pricing in.
Scan Hinge Health’s momentum against other fast moving healthcare names by checking our curated list of 34 healthcare AI stocks.
The business now carries a US$8.47b market value on US$720.06m of revenue and US$107.29m of net income. Do those foundations still justify taking on new risk for Hinge Health buyers at US$104.96?
Most Popular Narrative: 27.6% Undervalued
On the most followed view, Hinge Health’s fair value of $145.04 sits well above the recent $104.96 close, which puts the current share price at a meaningful discount to that narrative estimate.
Hinge Health has quickly distinguished itself as one of the most successful IPOs of 2025, combining rapid revenue growth, widening margins, and a scalable AI driven care model. The company’s focus on musculoskeletal (MSK) health; covering prevention, acute injury, chronic pain, and post‑surgical recovery, has resonated with employers and insurers, driving adoption across millions of contracted lives.
See why 1 investors see Hinge Health as 28% undervalued.
Result: Fair Value of $145.04 (UNDERVALUED)
Still, Hinge Health’s story could be knocked off course if regulatory scrutiny around digital MSK care tightens, or if large employer clients start to churn.
Find out about the key risks to this Hinge Health narrative.
Another View: What Hinge Health’s P/E Ratio Is Telling You
There is a very different message coming from plain P/E math. At about 78.9x earnings, Hinge Health trades well above the US Healthcare sector on 25.6x and peers on 46.2x, and more than double its own 37.1x fair ratio. This points to real valuation risk if sentiment cools.
For a closer look at how this earnings multiple stacks up against the market and what that gap could mean for future returns, See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
Sentiment around Hinge Health is clearly upbeat, so move quickly and test the numbers yourself instead of relying on any single narrative. To see which specific strengths our model flags as potential bright spots, review the 3 key rewards.
Looking for more investment ideas beyond Hinge Health?
If Hinge Health has your attention, do not stop there. Put a wider set of quality prospects on your radar before the next wave of moves passes you by.
- Target resilient income by scanning for companies in our 8 dividend fortresses that combine higher yields with balance sheets you can actually trust.
- Hunt for mispriced quality by working through the 33 high quality undervalued stocks and compare businesses where fundamentals look stronger than the market price implies.
- Zero in on sturdier foundations using the list of solid balance sheet and fundamentals (25 results) to focus on firms with financial profiles built to handle tougher conditions.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com